Related Experiment Video
Updated: Jul 18, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Butein Alleviates Non-Alcoholic Steatohepatitis in Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway
Chao Guo1,2, Yushan Zhang2, Huan Xue2
1Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, People's Republic of China.
Purpose:
Non-alcoholic steatohepatitis (NASH) is a prevalent liver disease characterized by steatosis, inflammation, and liver injury. Despite its increasing incidence, effective treatments are limited. Butein, a flavonoid with anti-cancer, anti-inflammatory, and antioxidant properties, has not been thoroughly studied for its potential therapeutic effects in NASH. This study aimed to evaluate the effects of butein in NASH using both in vivo and in vitro experimental models, with emphasis on elucidating the underlying molecular signaling mechanisms.
Methods:
The leptin-deficient (ob/ob) mouse model of NASH, induced by the Gubra amylase NASH (GAN) diet, was employed to assess the therapeutic effects and mechanistic pathways of butein treatment. In vitro investigations utilized palmitic acid-induced HepG2 human hepatocellular carcinoma cells and LX-2 hepatic stellate cells to explore butein's impact on oxidative stress, inflammatory responses, and fibrotic processes.
Results:
Butein treatment resulted in significant amelioration of glucolipid metabolism dysregulation, hepatic inflammation, and liver fibrosis in the mouse model, potentially mediated through modulation of the PDE4/cAMP/p-CREB signaling pathway. In in vitro experimental models, butein effectively attenuated lipid-induced oxidative stress in HepG2 cells and reduced inflammatory and fibrotic responses in LX-2 cells, demonstrating consistent protective effects across both experimental models.
Conclusion:
These findings establish the protective effects of butein against NASH progression through PDE4/cAMP/p-CREB pathway modulation, supporting its potential as a therapeutic candidate for NASH treatment pending further clinical validation.
Insights
Butein shows promise in treating non-alcoholic steatohepatitis (NASH). This flavonoid reduced liver inflammation and fibrosis in mouse models by modulating the PDE4/cAMP/p-CREB pathway.
Area of Science:
- Hepatology
- Pharmacology
- Molecular Biology
Background:
- Non-alcoholic steatohepatitis (NASH) is a growing liver disease with limited treatment options.
- Flavonoids, like butein, possess anti-inflammatory and antioxidant properties.
- Butein's therapeutic potential in NASH remains largely unexplored.
Purpose of the Study:
- To investigate the therapeutic effects of butein in experimental NASH models.
- To elucidate the molecular mechanisms underlying butein's action in NASH.
- To evaluate butein's impact on glucolipid metabolism, inflammation, and fibrosis.
Main Methods:
- Utilized a leptin-deficient (ob/ob) mouse model of NASH induced by a GAN diet.
- Employed in vitro models using HepG2 and LX-2 cells treated with palmitic acid.
- Assessed oxidative stress, inflammation, fibrotic markers, and the PDE4/cAMP/p-CREB pathway.
Main Results:
- Butein significantly improved glucolipid metabolism, reduced hepatic inflammation, and ameliorated liver fibrosis in mice.
- In vitro, butein attenuated palmitic acid-induced oxidative stress in HepG2 cells.
- Butein decreased inflammatory and fibrotic responses in LX-2 cells.
Conclusions:
- Butein demonstrates protective effects against NASH progression.
- The PDE4/cAMP/p-CREB signaling pathway is implicated in butein's therapeutic action.
- Butein is a potential therapeutic candidate for NASH, requiring further clinical studies.
